The Immune Response Corporation to Present at Rodman & Renshaw Techvest Global Healthcare Conference 2006

The Immune Response Corporation (OTCBB:IMNR) announced it willpresent an overview of the Company's immune-based therapies, now inPhase II clinical trials for multiple sclerosis (MS) and humanimmunodeficiency virus (HIV), at the Rodman & Renshaw 3rd AnnualTechvest Global Healthcare Conference 2006 in Monte Carlo, Monaco,Tuesday, May 16, 2006. The conference is a leading annualbiotechnology forum for global investors and financial professionals.

Mr. Michael Green, The Immune Response Corporation's CFO and COO,will make the presentation. Mr. Green will discuss Immune Response'sdrug development pipeline and status of the Phase II clinical trialsnow in progress for NeuroVax(TM) for the treatment of MS, and IR103,for the treatment of HIV. NeuroVax is a T-cell receptor peptide-basedimmunotherapy, and IR103 is based on the Company's patentedwhole-inactivated virus technology, co-invented by Dr. Jonas Salk.

Mr. Green stated, "We are focused on rigorous clinical testing ofour most promising immune-based therapies for MS and HIV, which areboth in Phase II trials. Each trial is supervised by distinguishedscientific and clinical experts from our respective MS and HIVScientific Advisory Boards. Results from earlier trials have been veryencouraging and give us cause to be excited about future developmentsfor the Company."

Mr. Green added, "We recently announced that NeuroVax, theCompany's T-cell receptor peptide vaccine candidate, induces increasedFOXP3 expression resulting in re-establishment of normal levels of theFOXP3+ regulatory T-cells, believed to be important in controlling thedevelopment of MS. We anticipate beginning a large, double-blinded,placebo controlled study for NeuroVax this year."

The full voice and PowerPoint presentation may be heard live onthe Internet via web cast by visitinghttp://wsw.com/webcast/rrshq8/imnr beginning at 6:20 a.m. Eastern time(12:20 p.m. Monaco). The Company suggests you review the site prior tothe web cast to ensure that your computer is configured properly.

An archived voice and PowerPoint version of the presentation willbe available for 90 days after the live presentation by accessinghttp://wsw.com/webcast/rrshq8/imn.

EVENT: Rodman & Renshaw 3rd Annual Techvest Global Healthcare
Conference 2006

WHEN: Tuesday, May 16, 2006

TIME: 6:20 a.m. ET U.S. (archived for 90 days at
http://wsw.com/webcast/rrshq8/imnr)

The Rodman & Renshaw Healthcare Conference, to be attended byinvestors, venture capitalists, company executives, scientists andothers, is scheduled for May 15-16 at the Le Meridien Beach PlazaHotel, Monte Carlo, Monaco. It will include presentations by anestimated 150 emerging-growth companies. For more information aboutthe Rodman & Renshaw Healthcare Conference in Monaco, please visithttp://www.rodmanandrenshaw.com.

About The Immune Response Corporation

The Immune Response Corporation is an immuno-pharmaceuticalcompany focused on developing products to treat autoimmune andinfectious diseases. The Company's lead immune-based therapeuticproduct candidates are NeuroVax(TM) for the treatment of MS and IR103for the treatment of HIV infection. Both of these therapies are inPhase II clinical development and are designed to stimulatepathogen-specific immune responses aimed at slowing or halting therate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cellreceptor (TCR) peptide technology, has shown potential clinical valuein the treatment of relapsing forms of MS. NeuroVax(TM) has been shownto stimulate strong, disease-specific cell-mediated immunity in nearlyall patients treated and appears to work by enhancing levels of FOXP3+Treg cells that are able to down-regulate the activity of pathogenicT-cells that cause MS. Increasing scientific findings have associateddiminished levels of FOXP3+ Treg cell responses with the pathogenesisand progression of MS and other autoimmune diseases such as rheumatoidarthritis (RA), psoriasis and Crohn's disease. In addition to MS, theCompany has open Investigational New Drug Applications (IND) with theFDA for clinical evaluation of TCR peptide-based immune-basedtherapies for RA and psoriasis.

IR103 is based on the Company's patented whole-inactivated virustechnology, co-invented by Dr. Jonas Salk and indicated to be safe andimmunogenic in extensive clinical studies of REMUNE(R), the Company'sfirst generation HIV product candidate. IR103 is a more potentformulation that combines its whole-inactivated antigen with asynthetic Toll-like receptor (TLR-9) agonist to generate enhancedHIV-specific immune responses. The Company is currently testing IR103in two Phase II clinical studies as a first-line treatment fordrug-naive HIV-infected individuals not yet eligible forantiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The ImmuneResponse Corporation and are not approved by any regulatory agenciesin any country at this time. Please visit The Immune ResponseCorporation at www.imnr.com for more information.

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas should, could, will, might, plan, projection, forecast, expect,guidance, potential and developing.

Actual results could vary materially from those expected due to avariety of risk factors, including whether the Company will continueas a going concern and successfully raise proceeds from financingactivities sufficient to fund operations and additional clinicaltrials of its product candidates, the uncertainty of successfulcompletion of any such clinical trials, the fact that the Company hasnot succeeded in commercializing any drug, the risk that its productcandidates might not prove to be effective as either a therapeutic orpreventive vaccine, whether future trials will be conducted andwhether the results of such trials will coincide with the results ofits product candidates in preclinical trials and/or earlier clinicaltrials. A more extensive set of risks is set forth in The ImmuneResponse Corporation's SEC filings including, but not limited to, itsAnnual Report on Form 10-K for the year ended December 31, 2005. TheCompany undertakes no obligation to update the results of theseforward-looking statements to reflect events or circumstances aftertoday or to reflect the occurrence of unanticipated events.

NeuroVax(TM) is a trademark of The Immune Response Corporation.REMUNE(R) is a registered trademark of The Immune ResponseCorporation.